Navigation Links
Diamyd Gets Authorization to Begin Phase III Study in the US
Date:3/14/2008

STOCKHOLM, March 14 /PRNewswire-FirstCall/ -- Diamyd Medical AB (http://www.omxgroup.com, ticker: DIAM B; http://www.otcqx.com, ticker DMYDY). The FDA has given Diamyd Medical permission to start a Phase III clinical study in type 1 diabetes patients in the US with the therapeutic diabetes vaccine Diamyd(R).

(Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 )

"We are eager to start this study and to be able to offer this promising drug to our newly diagnosed type 1 diabetes patients", says Professor Jerry Palmer, University of Washington in Seattle, USA, who will be the Lead Investigator for the US study.

"We are extremely pleased with this progress," says Elisabeth Lindner, President and CEO of Diamyd Medical. "Over the past months we have received dozens of patient inquiries with requests to participate in our Phase III type 1 diabetes studies in the US and in Europe. It is very satisfying to be able to start the studies now."

The US Phase III study will enroll 306 new-onset type 1 diabetes patients, who are within 3 months of diagnosis. Results of the study will be analyzed 15 months after all patients have been enrolled. A parallel Phase III study is planned to be conducted in Europe and together, pending a positive outcome of the trials, these pivotal studies can be used for market registration of the drug.

In a previous Phase II study in young type 1 diabetes patients, Diamyd(R) showed efficacy in preserving the patients' own insulin producing capacity for at least 30 months. No safety concerns have to date been reported in any clinical study with Diamyd(R).

Company website: http://www.diamyd.com

Diamyd Medical AB (publ). Linnegatan 89 B, SE-115 23 Stockholm, Sweden

Disclaimer: This document contains certain statements relating to the progress, timing and completion of our research, development and clinical trials. These statements can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Diamyd Medical undertakes no obligation to publicly update such statements, whether because of new information, future events or otherwise, nor does Diamyd Medical give any guarantees that the statements, given or implied, are correct. This document is a translation from the Swedish original. No guarantees are made that the translation is free from errors.


'/>"/>
SOURCE Diamyd Medical AB (publ)
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Techne Corporation Announces Share Repurchase Authorization
3. Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
4. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
5. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
6. EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
7. ZARS Pharma Announces Marketing Authorization of Rapydan(R) in Europe
8. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
9. DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board
10. Genzyme Begins Major Expansion of Boston Manufacturing Facility
11. CalbaTech Issues Update; Beginning Training for Adult Stem Cell Collections in Atlanta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... ... delivery of product vigilance software to leading biopharmaceutical and medical device manufacturers and ... is a fully 21 CFR Part 11-compliant email client designed to provide product ...
(Date:1/19/2017)... , Jan. 19, 2017  ArmaGen, Inc., ... Schmidt , Ph.D., as chief executive officer, as ... directors. Dr. Schmidt brings to ArmaGen more than 17 ... research and development of biotherapeutics and pharmaceuticals. ... with the diverse experience and skillset necessary to ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... of Health (NIH) to update its Data Sharing Policy. Specifically, the nation’s leading ... grant applications subject to the existing policy. AMIA recommended that NIH earmark funding ...
(Date:1/19/2017)... ... January 19, 2017 , ... FireflySci Inc. is a go-getter type ... tremendous growth is accounted to two main factors. The first is the amazing ... of vendors supplying FireflySci products all around the world. , 2016 was a tremendous ...
Breaking Biology Technology:
(Date:1/6/2017)... , Jan. 5, 2017  Delta ID Inc., a ... scanning technology for automotive at CES® 2017. Delta ID ... ) to demonstrate the use of iris scanning as ... authenticate the driver in a car, and as a ... driving experience. Delta ID and Gentex will ...
(Date:12/22/2016)... -- As part of its longstanding mission to improve genetic literacy ... released its latest children,s book, titled The One ... topics of inheritance and variation of traits that are part ... school classrooms in the US. The book ... Killoran , whose previous book with 23andMe, You ...
(Date:12/19/2016)... BARCELONA , España y TORONTO , 19 ... fusión con Northern Biologics Inc. que permitirá el desarrollo acelerado de ... ensayos clínicos en varios tipos de tumor en 2017, con múltiples ... ... de su clase con objetivo en el factor inhibidor de leucemia ...
Breaking Biology News(10 mins):